CN Patent

CN116437958A — 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法

Assigned to Gilead Sciences Inc · Expires 2023-07-14 · 3y expired

What this patent protects

本发明提供了用于鉴定感染了HIV的患者群体的方法，该HIV能够由结合至HIV gp120 CD4结合位点(CD4bs)区域的抗体靶向。

USPTO Abstract

本发明提供了用于鉴定感染了HIV的患者群体的方法，该HIV能够由结合至HIV gp120 CD4结合位点(CD4bs)区域的抗体靶向。

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CN116437958A
Jurisdiction: CN
Classification: —
Expires: 2023-07-14
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.